Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology Patients
免疫肿瘤患者预测多重免疫组织化学分析的患者因素和样品预分析的评估
基本信息
- 批准号:10907058
- 负责人:
- 金额:$ 20.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2027-11-30
- 项目状态:未结题
- 来源:
- 关键词:4 year oldAccelerationAddressAffectAgeAlcoholsAntiemeticsAsianBiological AssayBiological MarkersBiopsyBlack raceBody mass indexCancer PatientCategoriesCharacteristicsClinicClinicalCollaborationsCytotoxic ChemotherapyDataDatabasesDependenceEastern Cooperative Oncology GroupEnsureEthnic OriginEvaluationExcisionFaceFormalinFreezingGenderGoalsGuidelinesHealth Care CostsHispanicIceImmunohistochemistryImmunooncologyImmunotherapyIschemiaKnowledgeLengthLymphocyteMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of urinary bladderMeasurementMeasuresMemorial Sloan-Kettering Cancer CenterMolecularNon-Small-Cell Lung CarcinomaOutcomeParaffin TissuePatientsPerformancePerformance StatusPharmacotherapyPhysiologicalProceduresProcessProspective StudiesProspective cohortProteinsProtocols documentationQualifyingRadiationResearchSamplingSiteSolidSpecificitySpecimenSteroidsTemperatureTestingTimeTissue SampleTissuesTranslationsTumor TissueVariantanti-PD-L1biobankcancer typecell typeclinical practicecohortcontextual factorsdiagnostic assaygastroesophageal cancerhistological slidesimmune checkpointimmunological statusinnovationmalignant breast neoplasmmelanomamultiplex assayneoplastic cellnext generationovertreatmentpatient variabilitypersonalized diagnosticspersonalized health carepredictive markerpredictive testpreservationprogrammed cell death ligand 1protein expressionsample fixationtissue fixingtumor
项目摘要
Project Summary/Abstract
Therapies against immunologic checkpoint proteins, such as PD-L1, have revolutionized the treatment of multiple
malignancies, such as malignant melanoma, lung cancer, bladder cancer, or gastroesophageal cancer. All of these
therapies depend on predictive biomarker assays for PD-L1 protein expression in tumor tissue to identify patients who
will most likely respond. PD-L1 assays face two significant challenges: (i) they often need to be performed on small tissue
biopsies where tumor tissue is limited and (ii) the threshold for positivity by immunohistochemistry (1%) is very small,
highlighting crucial dependence on utmost precision and pre-analytical sample validity.
To address the issue of small and limited samples in biopsies, we have developed a chromogenic multiplexed
immunohistochemical assay that combines PD-L1 assessment with tissue and cell type-specific markers to provide a
combined diagnostic and predictive assay on a single histologic slide. To move multiplexed assays around PD-L1 into the
clinic, there exists an important knowledge gap: what are the patient-specific factors and specimen-related pre-analytical
variables that can influence the readout of PD-L1 positivity? Very limited knowledge is available about these variables.
Importantly, because the PD-L1 positivity threshold is so low and requires the reliable separation of two very small
numbers (<1% vs. ≥1%), even minute pre-analytical variabilities would be expected to have significant negative impact on
assay validity. In that respect, PD-L1 testing in tissue is particularly in need of extensive characterization and control of
pre-analytical variability, even more so than other assays whose cut-off points lie in more favorable ranges.
Our proposal is based on the hypothesis that both patient-specific factors (such as molecular features of the cancer,
current immune status, prior drug therapy, etc.) and specimen-related factors (such as timing of biopsy, size of tissue,
ischemic time, fixation protocol, etc.) can significantly influence subsequent biomarker measurements. We further
hypothesize that solid knowledge about these influences will allow controlling for and mitigating patient-specific and
specimen-related effects and will lead to more accurate and valid biomarker assessment. Aim 1: We will create a cohort
to test the influence of patient-specific context factors. We will make use of our extensive immuno-oncology database
and biobank of >5,000 patients. Aim 2: We will test how specimen-related pre-analytical variables affect the assay using
a wide variety of fresh, frozen, and formalin fixed tissue types and sizes. Aim 3: Once we have defined optimal patient-
specific and specimen-related procedures, we will validate our multiplex assay in a prospective cohort of immunotherapy
patients at MSKCC.
Significance: This project will yield abundant data about the pre-analytical variables that influence a PD-L1 multiplex
immunohistochemistry assay. These data will inform optimal specimen acquisition and handling and strategies for
avoiding or mitigating inaccurate assay results. Innovation: This will be the first study to systematically explore both
patient context factors and specimen pre-analytics in multiplexed immunohistochemical testing for immuno-oncology.
Our close collaboration with commercial test developers as part of our research team will accelerate the translation of
our scientific findings into optimized assays for the direct benefit of patients.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael H. A. Roehrl其他文献
Michael H. A. Roehrl的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael H. A. Roehrl', 18)}}的其他基金
Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology Patients
免疫肿瘤患者预测多重免疫组织化学分析的患者因素和样品预分析的评估
- 批准号:
10451186 - 财政年份:2022
- 资助金额:
$ 20.11万 - 项目类别:
Proteomic Characterization of Pancreatic Neuroendocrine Tumors and Metastatic Progression
胰腺神经内分泌肿瘤的蛋白质组学特征和转移进展
- 批准号:
10472649 - 财政年份:2021
- 资助金额:
$ 20.11万 - 项目类别:
Proteomic Characterization of Pancreatic Neuroendocrine Tumors and Metastatic Progression
胰腺神经内分泌肿瘤的蛋白质组学特征和转移进展
- 批准号:
10290014 - 财政年份:2021
- 资助金额:
$ 20.11万 - 项目类别:
Proteomic Characterization of Genomically Complex Sarcomas
基因组复杂肉瘤的蛋白质组学表征
- 批准号:
10039807 - 财政年份:2020
- 资助金额:
$ 20.11万 - 项目类别:
相似海外基金
SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
- 批准号:
2400967 - 财政年份:2024
- 资助金额:
$ 20.11万 - 项目类别:
Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328975 - 财政年份:2024
- 资助金额:
$ 20.11万 - 项目类别:
Continuing Grant
EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
- 批准号:
NE/Y000080/1 - 财政年份:2024
- 资助金额:
$ 20.11万 - 项目类别:
Research Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
- 批准号:
10112700 - 财政年份:2024
- 资助金额:
$ 20.11万 - 项目类别:
Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328973 - 财政年份:2024
- 资助金额:
$ 20.11万 - 项目类别:
Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328972 - 财政年份:2024
- 资助金额:
$ 20.11万 - 项目类别:
Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332916 - 财政年份:2024
- 资助金额:
$ 20.11万 - 项目类别:
Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332917 - 财政年份:2024
- 资助金额:
$ 20.11万 - 项目类别:
Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328974 - 财政年份:2024
- 资助金额:
$ 20.11万 - 项目类别:
Continuing Grant
Radiation GRMHD with Non-Thermal Particle Acceleration: Next-Generation Models of Black Hole Accretion Flows and Jets
具有非热粒子加速的辐射 GRMHD:黑洞吸积流和喷流的下一代模型
- 批准号:
2307983 - 财政年份:2023
- 资助金额:
$ 20.11万 - 项目类别:
Standard Grant